6V6L

Co-structure of human glycogen synthase kinase beta with 1-(6-((2-((6-amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one

Summary for 6V6L

• Entry DOI: 10.2210/pdb6v6l/pdb
• Descriptor: Glycogen synthase kinase-3 beta, 1-(6-((2-((6-amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one, PHOSPHATE ION, ... (4 entities in total)
• Functional Keywords: kinase, transferase
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 1
• Total formula weight: 47507.56

Authors

Bussiere, D.E.,Fang, E.,Shu, W. (deposition date: 2019-12-05, release date: 2020-01-15, Last modification date: 2024-11-20)

Primary citation

Ramurthy, S.,Pfister, K.B.,Boyce, R.S.,Brown, S.P.,Costales, A.Q.,Desai, M.C.,Fang, E.,Levine, B.H.,Ng, S.C.,Nuss, J.M.,Ring, D.B.,Shafer, C.M.,Shu, W.,Subramanian, S.,Wagman, A.S.,Wang, H.,Bussiere, D.E.
Discovery and optimization of novel pyridines as highly potent and selective glycogen synthase kinase 3 inhibitors.
Bioorg.Med.Chem.Lett., 30:126930-126930, 2020

PubMed Abstract: Glycogen synthase kinase-3 plays an essential role in multiple biochemical pathways in the cell, particularly in regards to energy regulation. As such, Glycogen synthase kinase-3 is an attractive target for pharmacological intervention in a variety of disease states, particularly non-insulin dependent diabetes mellitus. However, due to homology with other crucial kinases, such as the cyclin-dependent protein kinase CDC2, developing compounds that are both potent and selective is challenging. A novel series of derivatives of 5-nitro-N2-(2-(pyridine-2ylamino)ethyl)pyridine-2,6-diamine were synthesized and have been shown to potently inhibit glycogen synthase kinase-3 (GSK3). Potency in the low nanomolar range was obtained along with remarkable selectivity. The compounds activate glycogen synthase in insulin receptor-expressing CHO-IR cells and in primary rat hepatocytes, and have acceptable pharmacokinetics and pharmacodynamics to allow for oral dosing. The X-ray co-crystal structure of human GSK3-β in complex with compound 2 is reported and provides insights into the structural determinants of the series responsible for its potency and selectivity.

PubMed: 31926786
DOI: 10.1016/j.bmcl.2019.126930

Experimental method

X-RAY DIFFRACTION (2.19 Å)